STERLING NAMES ROBIN MILLS VP-STRATEGIC RESOURCES/OTC MEDICINES under a management reorganization announced Sept. 27. "In this new position, effective Oct. 1, Mr. Mills will be responsible for global OTC medicines strategy development, product development and the enhancement of worldwide OTC marketing operations," the company explained. The move effectively combines Sterling's two domestic OTC marketing organizations, Winthrop Consumer Products and Glenbrook Labs, under the leadership of Mills. It also demonstrates the interest of Sterling's new parent, Kodak, in the OTC business. With the top OTC appointment, Mills is one of the leading Sterling holdovers following the merger. Louis Mattis, who assumed the Sterling presidency on Aug. 1 after the departure of James Andress, heads the Sterling group at Kodak. Mills has experience with four companies in the proprietary medicines field. Prior to joining Sterling in 1984 as president of Glenbrook Labs, he headed Chattem's consumer products division. Previously, Mills was VP-marketing at Revlon's (now Beecham's) Norcliff Thayer division, and before that a product manager with Rich-Vicks. He was elected a Sterling corporate VP shortly after joining the company. "We view this assignment as critically important to the future success of our proprietary medicines business globally," Sterling Chairman Leo Thomas, PhD, and President Louis Mattis emphasized. Mills is succeeded as president of Glenbrook Labs by William Godfrey, who has been president of Winthrop Consumer since 1986. Godfrey spent 12 years in various sales and marketing positions at Richardson-Merrell and later worked for Bausch & Lomb as president of the firm's personal products division. In the ethical drug area, Harry Shoff, president of Winthrop Pharmaceuticals, was given the additional responsibilities of Cooke-Waite and WinVet, Sterling's dental care and veterinary units, respectively. Shoff joined the company in October 1985 as exec VP of Winthrop and became president three months later. Both Shoff and Godfrey have also been elected Sterling corporate VPs. Ex-Ciba exec Paul Baehr, VP-strategic resources/ethical medicines, is responsible for prescription product global strategy and R&D. Finally, Herbert McKenzie, becomes president, Sterling International, succeeding Louis Mattis. He assumes responsibility for Sterling's non-U.S. ethical and OTC pharmaceutical operations. McKenzie joined Sterling in 1980 as exec VP-Hilton-Davis Chemicals, becoming president as well as a corporate VP the following year. He was named president of the Sterling Chemical Group upon its establishment in 1982. Under a 1985 reorganization of Sterling International, McKenzie was named president of JCAP (Japan, Canada, Australasia/Pacific).
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Health Canada’s proposal to no longer require biosimilar manufacturers to prove the safety and efficacy of their product through Phase III clinical trials marks a pivotal change in Canada’s regulatory approach.
Key expert panel go-ahead with a trial waiver put’s Eisai's Alzheimer's therapy on track for a debut in India where tailored pricing will be pivotal. Lilly’s Kisunla is also under regulatory review.
Highlights from day one of the BIO convention include advice for firms hoping to go public, a call for companies to push the US Congress on rare disease priority review vouchers, and updates on next-generation gene therapies.
